Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -68.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 0% | 99.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -213% | -160.2% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 1,021.9% | -63.1% |
| EPS Diluted | -0.26 | -0.76 | 2.7 | -1.04 |
| % Growth | 65.8% | -128.1% | 359.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |